Adults: For adults having autologous HPCT, the recommended dose of Thiotepa in haematological diseases is between 125 mg/m2/day (3.38 mg/kg/day) and 300 mg/m2/day (8.10 mg/kg/day). It is given as a single daily infusion on 2 up to 4 consecutive days before the transplant, depending on which other chemotherapeutic medicinal products are combined with it. The total cumulative dose must not go above 900 mg/m2 (24.32 mg/kg) during the entire conditioning treatment.
Lymphoma: the dose is again between 125 mg/m2/day (3.38 mg/kg/day) and 300 mg/m2/day (8.10 mg/kg/day), as a single daily infusion on 2 up to 4 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total maximum cumulative dose is 900 mg/m2 (24.32 mg/kg) during the entire conditioning treatment.
Central nervous system lymphoma: the recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion for 2 consecutive days before autologous HPCT. The total maximum cumulative dose during the entire conditioning treatment is 370 mg/m2 (10 mg/kg).
Multiple myeloma: the dose is between 150 mg/m2/day (4.05 mg/kg/day) and 250 mg/m2/day (6.76 mg/kg/day), as a single daily infusion for 3 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total cumulative dose must not exceed 750 mg/m2 (20.27 mg/kg) during the entire conditioning treatment.
Solid tumours: the recommended dose is between 120 mg/m2/day (3.24 mg/kg/day) and 250 mg/m2/day (6.76 mg/kg/day), divided in one or two daily infusions. It is given on 2 up to 5 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total maximum cumulative dose is 800 mg/m2 (21.62 mg/kg) during the entire conditioning treatment.
Breast cancer: the dose is between 120 mg/m2/day (3.24 mg/kg/day) and 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion, on 3 up to 5 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total cumulative dose must not exceed 800 mg/m2 (21.62 mg/kg) during the entire conditioning treatment.
CNS tumours: the recommended dose is between 125 mg/m2/day (3.38 mg/kg/day) and 250 mg/m2/day (6.76 mg/kg/day), divided in one or two daily infusions. It is given on 3 up to 4 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total maximum cumulative dose is 750 mg/m2 (20.27 mg/kg) during the entire conditioning treatment.
Ovarian cancer: the recommended dose is 250 mg/m2/day (6.76 mg/kg/day) as a single daily infusion on 2 consecutive days before autologous HPCT. The total maximum cumulative dose during the entire conditioning treatment is 500 mg/m2 (13.51 mg/kg).
Germ cell tumours: the dose is between 150 mg/m2/day (4.05 mg/kg/day) and 250 mg/m2/day (6.76 mg/kg/day), as a single daily infusion for 3 consecutive days before autologous HPCT, depending on the combination with other chemotherapeutic medicinal products. The total cumulative dose must not exceed 750 mg/m2 (20.27 mg/kg) during the entire conditioning treatment.
For allogeneic HPCT in haematological diseases, the recommended dose is between 185 mg/m2/day (5 mg/kg/day) and 481 mg/m2/day (13 mg/kg/day), divided in one or two daily infusions. It is given on 1 up to 3 consecutive days before allogeneic HPCT, depending on the combination with other chemotherapeutic medicinal products. The total maximum cumulative dose is 555 mg/m2 (15 mg/kg) during the entire conditioning treatment.
Lymphoma: the recommended dose is 370 mg/m2/day (10 mg/kg/day), divided in two daily infusions before allogeneic HPCT. The total maximum cumulative dose during the entire conditioning treatment is 370 mg/m2 (10 mg/kg).
Multiple myeloma: the recommended dose is 185 mg/m2/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT. The total maximum cumulative dose during the entire conditioning treatment is 185 mg/m2 (5 mg/kg).
Leukaemia: the dose is between 185 mg/m2/day (5 mg/kg/day) and 481 mg/m2/day (13 mg/kg/day), divided in one or two daily infusions. It is given on 1 up to 2 consecutive days before allogeneic HPCT, depending on the combination with other chemotherapeutic medicinal products. The total cumulative dose must not exceed 555 mg/m2 (15 mg/kg) during the entire conditioning treatment.
Thalassemia: the recommended dose is 370 mg/m2/day (10 mg/kg/day), divided in two daily infusions and given before allogeneic HPCT. The total maximum cumulative dose during the entire conditioning treatment is 370 mg/m2 (10 mg/kg).
